<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01828619</url>
  </required_header>
  <id_info>
    <org_study_id>PKUIH-201303</org_study_id>
    <nct_id>NCT01828619</nct_id>
  </id_info>
  <brief_title>Study of New RIC Regimen of BuFlu in Older and/or Intolerable Patients</brief_title>
  <official_title>The Study of New RIC Regimen of BuFlu in Older or Intolerable Patients With Hematologic Malignant Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the new RIC regimen, containing of low dose
      of Bu (9.6mg/kg)and fludarabine without ATG, is suitable and effective in treating aged
      and/or intolerable patients with hematologic malignant disease, who undergoes allogenic stem
      cell transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>February 2013</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>stem cell engraftment</measure>
    <time_frame>30day post transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>toxicity and treatment related mortality</measure>
    <time_frame>100day and 1 year post transplantation</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>modified BuFlu, HSCT, elder/intolerable</arm_group_label>
    <description>The study group is the hematlogic malignant patients that older than 55years and/or with severe concurrent medical conditions, who will undergo HLA-matced allogenic HSCT to cure the disease. The patients will received a modified BuFlu conditioning.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>modified BuFlu conditioning</intervention_name>
    <description>The regimen consisted of hydroxyurea 80 mg/kg on d -10; cytorabine 2 g/m2 on d -9; busulfan 3.2mg/kg/day iv. ×3days( on d -8 to -6); Flu30mg/m^2 i.v.×5days(on d-6 to-2) and semustine 250 mg/m2 on d -3.</description>
    <arm_group_label>modified BuFlu, HSCT, elder/intolerable</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population is patients with hematologic malignant diseases, who will undergo HLA
        matched HSCT.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosed of hematologic malignant disease

          -  will undergo HLA matced HSCT

          -  age &gt;=55years

          -  &lt;55year and intolerable to standard myeloablative conditioning

        Exclusion Criteria:

          -  KPS status &lt;70

          -  cardiac EF&lt;50%

          -  creatine clearance &lt;50 ml/min

          -  ALT more than 10 times of upper normal limit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>XiaoJun Huang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People's Hospital, Department of Hematology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Barrett AJ, Savani BN. Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia. 2006 Oct;20(10):1661-72. Epub 2006 Jul 27. Review.</citation>
    <PMID>16871277</PMID>
  </reference>
  <reference>
    <citation>de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, Shpall EJ, Shahjahan M, Pierre B, Giralt S, Korbling M, Russell JA, Champlin RE, Andersson BS. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004 Aug 1;104(3):857-64. Epub 2004 Apr 8.</citation>
    <PMID>15073038</PMID>
  </reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2013</study_first_submitted>
  <study_first_submitted_qc>April 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2013</study_first_posted>
  <last_update_submitted>April 9, 2013</last_update_submitted>
  <last_update_submitted_qc>April 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>FENGRONG WANG</investigator_full_name>
    <investigator_title>Department of Hematology</investigator_title>
  </responsible_party>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <keyword>Busulfan</keyword>
  <keyword>Fludarabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

